Description de l'entreprise
CSL is a global specialty biotherapeutics company that develops and delivers innovative biotherapies that save lives, and help people with life-threatening medical conditions live full lives. CSL has acquired a number of companies. They include: Aventis Behring, which is now known as global biotech leader CSL Behring, U.S. plasma collector Nabi, which helped to form the world's premier plasma collection company in CSL Plasma, the Novartis influenza vaccine business, now integrated and known as Seqirus, the world's second largest influenza vaccines company and Calimmune, a leader in gene-modification and cell delivery technology.
Conseil d'administration & Conseil de surveillance
| PDG |
| Paul Perreault |
| Conseil d'administration |
| Alan Wills, Bill Campbell, Bill Mezzanotte, Elizabeth Walker, Greg Boss, John Levy, Mark Hill, Paul McKenzie |
| Conseil de surveillance |
| Dr. Brian McNamee, Abbas Hussain, Bruce Brook, Carolyn Hewson, Dr. Megan Clark, Fiona Mead, Marie McDonald, Pascal Soriot, Paul Perreault, Professor Andrew Cuthbertson |
Données de l'entreprise
| Nom: |
CSL Ltd. |
| Adresse: |
Poplar Road 45,Parkville VIC 3052, Australia |
| Téléphone: |
+61-3-9389-1911 |
| Fax: |
+61-3-9389-1434 |
| Courriel: |
-
|
| Internet: |
www.csl.com.au/ |
| Industrie: |
Healthcare |
| Secteur: |
Pharmaceutical Industry |
| Sous-secteur: |
Pharmaceuticals |
| Fin de l'exercice financier: |
30/06 |
| Flotte libre: |
42.01% |
| IPO date: |
30/05/1994 |
Relations avec les investisseurs
| Nom: |
Mark Dehring |
| Téléphone IR: |
+61-3-9389-3407 |
| IR-Fax: |
- |
| E-mail IR: |
mark.dehring@csl.com.au
|
